Fabrice Prunier

Fabrice Prunier

Auto-generated profile, based on publicly available information

Fabrice Prunier

LUNAM Université, Angers, France

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2021 in Circulation
Verified
Journal Article
Open access
PDF file
NMNathan Mewton
Nathan Mewton
FRFrançois Roubille
François Roubille
DBDidier Bresson
Didier Bresson
CPCyril Prieur
Cyril Prieur
CBClaire Bouleti
Claire Bouleti
DADenis Angoulvant
Denis Angoulvant
Background: Inflammation is a key factor of myocardial damage in reperfused ST-segment–elevation myocardial infarction. We hypothesized that colchicine, a potent anti-inflammatory agent, may reduce infarct size (IS) and left ventricular (LV) remodeling at the acute phase of ST-segment–elevation myocardial infarction. Methods: In this double-blind multicenter trial, we randomly assigned patients admitted for a first episode of ST-segment–elevation myocardial infarction referred for primary percutaneous coronary intervention to receive oral colchicine (2-mg loading dose followed by 0.5 mg twice a day) or matching placebo from admission to day 5. The primary efficacy outcome was IS determined by cardiac magnetic resonance imaging at 5 days. The relative LV end-diastolic volume change at 3 months and IS at 3 months assessed by cardiac magnetic resonance imaging were among the secondary outcomes. Results: We enrolled 192 patients, 101 in the colchicine group and 91 in the control group. At 5 days, the gadolinium enhancement–defined IS did not differ between the colchicine and placebo groups with a mean of 26 interquartile range (IQR) [16–44] versus 28.4 IQR [14–40] g of LV mass, respectively ( P =0.87). At 3 months follow-up, there was no significant difference in LV remodeling between the colchicine and placebo groups with a +2.4% (IQR, –8.3% to 11.1%) versus –1.1% (IQR, –8.0% to 9.9%) change in LV end-diastolic volume ( P =0.49). Infarct size at 3 months was also not significantly different between the colchicine and placebo groups (17 IQR [10–28] versus 18 IQR [10–27] g of LV mass, respectively; P =0.92). The incidence of gastrointestinal adverse events during the treatment period was greater with colchicine than with placebo (34% versus 11%, respectively; P =0.0002). Conclusions: In this randomized, placebo-controlled trial, oral administration of high-dose colchicine at the time of reperfusion and for 5 days did not reduce IS assessed by cardiac magnetic resonance imaging. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03156816.

11 August 2011 in Basic Research in Cardiology
Verified
Journal Article
Closed access
PDF file
STSophie Tamareille
Sophie Tamareille
VMVictor Mateus
Victor Mateus
NGNehmat Ghaboura
Nehmat Ghaboura
JJJulien Jeanneteau
Julien Jeanneteau
ACAnne Croué
Anne Croué
FPFabrice Prunier
Fabrice Prunier

10 January 2014 in Basic Research in Cardiology
Verified
Journal Article
Closed access
PDF file
FPFabrice Prunier
Fabrice Prunier
DADenis Angoulvant
Denis Angoulvant
CEChristophe Saint Etienne
Christophe Saint Etienne
EVEmmanuelle Vermes
Emmanuelle Vermes
MGMartine Gilard
Martine Gilard
AFAlain Furber
Alain Furber

1 January 2013 in Frontiers in Genetics
Verified
Journal Article
Open access
GLGeorges LEFTHERIOTIS
Georges LEFTHERIOTIS
LOLoukman OMARJEE
Loukman OMARJEE
OSOlivier Le Saux
Olivier Le Saux
DHDaniel Henrion
Daniel Henrion
PAPierre Abraham
Pierre Abraham
LMLudovic Martin
Ludovic Martin
Vascular calcification is a complex and dynamic process occurring in various physiological conditions such as aging and exercise or in acquired metabolic disorders like diabetes or chronic renal insufficiency. Arterial calcifications are also observed in several genetic diseases revealing the important role of unbalanced or defective anti- or pro-calcifying factors. Pseudoxanthoma elasticum (PXE) is an inherited disease (OMIM 264800) characterized by elastic fiber fragmentation and calcification in various soft conjunctive tissues including the skin, eyes, and arterial media. The PXE disease results from mutations in the ABCC6 gene, encoding an ATP-binding cassette transporter primarily expressed in the liver, kidneys suggesting that it is a prototypic metabolic soft-tissue calcifying disease of genetic origin. The clinical expression of the PXE arterial disease is characterized by an increased risk for coronary (myocardial infarction), cerebral (aneurysm and stroke), and lower limb peripheral artery disease. However, the structural and functional changes in the arterial wall induced by PXE are still unexplained. The use of a recombinant mouse model inactivated for the Abcc6 gene is an important tool for the understanding of the PXE pathophysiology although the vascular impact in this model remains limited to date. Overlapping of the PXE phenotype with other inherited calcifying diseases could bring important informations to our comprehension of the PXE disease.

28 October 2010 in Basic Research in Cardiology
Verified
Journal Article
Closed access
PDF file
NGNehmat Ghaboura
Nehmat Ghaboura
STSophie Tamareille
Sophie Tamareille
PDPierre-Henri Ducluzeau
Pierre-Henri Ducluzeau
LGLinda Grimaud
Linda Grimaud
LLLaurent Loufrani
Laurent Loufrani
FPFabrice Prunier
Fabrice Prunier

5 February 2015 in Basic Research in Cardiology
Verified
Journal Article
Closed access
PDF file
SPSophie Le Page
Sophie Le Page
TBTheodora Bejan-Angoulvant
Theodora Bejan-Angoulvant
DADenis Angoulvant
Denis Angoulvant
FPFabrice Prunier
Fabrice Prunier